CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Rhythm Pharmaceuticals Inc - RYTM CFD

55.99
2.85%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.22
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023512 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023512%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00129 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.00129%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 57.63
Open 58.12
1-Year Change 18.42%
Day's Range 55.99 - 58.12
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 21, 2025 55.99 -1.97 -3.40% 57.96 58.27 55.84
Feb 20, 2025 57.63 0.93 1.64% 56.70 58.28 56.53
Feb 19, 2025 57.90 1.07 1.88% 56.83 58.10 56.45
Feb 18, 2025 57.40 0.69 1.22% 56.71 57.56 55.97
Feb 14, 2025 56.62 -1.27 -2.19% 57.89 58.18 56.46
Feb 13, 2025 57.51 1.83 3.29% 55.68 58.54 55.68
Feb 12, 2025 57.58 1.33 2.36% 56.25 57.58 55.75
Feb 11, 2025 57.53 0.13 0.23% 57.40 57.95 56.96
Feb 10, 2025 58.43 -0.83 -1.40% 59.26 59.27 57.83
Feb 7, 2025 59.12 -0.43 -0.72% 59.55 60.05 58.59
Feb 6, 2025 59.90 -0.53 -0.88% 60.43 60.44 59.05
Feb 5, 2025 60.93 0.68 1.13% 60.25 62.04 59.02
Feb 4, 2025 59.85 0.90 1.53% 58.95 60.11 58.10
Feb 3, 2025 59.33 1.34 2.31% 57.99 60.22 57.62
Jan 31, 2025 59.31 0.81 1.38% 58.50 60.50 58.45
Jan 30, 2025 59.16 1.46 2.53% 57.70 59.42 57.20
Jan 29, 2025 57.11 1.07 1.91% 56.04 57.39 56.04
Jan 28, 2025 56.71 1.10 1.98% 55.61 57.59 55.07
Jan 27, 2025 56.37 0.93 1.68% 55.44 58.83 55.44
Jan 24, 2025 57.69 1.12 1.98% 56.57 58.08 56.30

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Rhythm Pharma Company profile

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). Its lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. It is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. It targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Rhythm Pharmaceuticals Inc revenues increased from $0K to $3.2M. Net loss decreased 48% to $69.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$3.04 to -$1.40.

Industry: Bio Therapeutic Drugs

222 Berkeley Street
12th Floor Boston
BOSTON
MASSACHUSETTS 02116
US

People also watch

XRP/USD

2.59 Price
+2.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01294

US100

21,594.40 Price
-2.120% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 22:00 (UTC)
Spread 7.0

BTC/USD

96,694.45 Price
+1.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

ETH/USD

2,760.24 Price
+4.610% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 690,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading